^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: Relapsed/refractory therapy...Preferred regimens…Venetoclax + rituximab (category 1)
